Recovery
Thymosin Beta-4
Also called Tβ4, RGN-352
per administration
It has been used in people, but no trial has settled how much or how often.
The human evidence for Thymosin Beta-4 used the intravenous route. The draw worked out here assumes a subcutaneous injection, so the amount is not a direct read-across.
Quick start
Thymosin Beta-4 at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 42–1260 mg per administration
- How often
- Every day
- Where
- Intravenous (clinical setting)
- Time to steady level
- ~12.5 days — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Thymosin Beta-4 describe 42–1260 mg per administration. Descriptive only, not a recommendation.
Thymosin β4 estimates vary widely; the TB-500 fragment page carries the same rough figure. Read as order-of-magnitude.
The full protein, distinct from the TB-500 fragment sold under that name. Human evidence is an intravenous safety study, so no subcutaneous schedule is established and no schedule table is shown; figures do not transfer to the fragment. The intravenous amounts studied (42–1260 mg) do not map onto a research vial, so the size shown is nominal.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 4.13× single dose
- Time to steady state
- 12.5days
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Ruff D et al., Ann N Y Acad Sci 2010;1194:223First-in-human intravenous thymosin β4 (RGN-352) at 42–1260 mg was assessed for safety in volunteers; no subcutaneous schedule was fixed.
- Thymosin β4 preclinical repair literatureThe full protein's human data is limited to intravenous safety work; it is the parent molecule of the TB-500 fragment, and figures do not carry between the two.